The inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)